AU2020417185B2 - Composition and therapy for treatment of gag reflexes - Google Patents

Composition and therapy for treatment of gag reflexes

Info

Publication number
AU2020417185B2
AU2020417185B2 AU2020417185A AU2020417185A AU2020417185B2 AU 2020417185 B2 AU2020417185 B2 AU 2020417185B2 AU 2020417185 A AU2020417185 A AU 2020417185A AU 2020417185 A AU2020417185 A AU 2020417185A AU 2020417185 B2 AU2020417185 B2 AU 2020417185B2
Authority
AU
Australia
Prior art keywords
composition
patient
sodium chloride
approximately
applicator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020417185A
Other languages
English (en)
Other versions
AU2020417185A1 (en
Inventor
Deshka OLSON
Robert Olson
Wayne PROVOST
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Innovations LLC
Original Assignee
Orion Innovations LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Innovations LLC filed Critical Orion Innovations LLC
Publication of AU2020417185A1 publication Critical patent/AU2020417185A1/en
Application granted granted Critical
Publication of AU2020417185B2 publication Critical patent/AU2020417185B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020417185A 2019-12-30 2020-12-11 Composition and therapy for treatment of gag reflexes Active AU2020417185B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962954966P 2019-12-30 2019-12-30
US62/954,966 2019-12-30
US17/100,677 US20210196748A1 (en) 2019-12-30 2020-11-20 Composition and therapy for treatment of gag reflexes
US17/100,677 2020-11-20
PCT/US2020/064604 WO2021138025A1 (en) 2019-12-30 2020-12-11 Composition and therapy for treatment of gag reflexes

Publications (2)

Publication Number Publication Date
AU2020417185A1 AU2020417185A1 (en) 2022-07-21
AU2020417185B2 true AU2020417185B2 (en) 2026-03-12

Family

ID=76545400

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020417185A Active AU2020417185B2 (en) 2019-12-30 2020-12-11 Composition and therapy for treatment of gag reflexes

Country Status (7)

Country Link
US (5) US20210196748A1 (https=)
EP (1) EP4084869A4 (https=)
JP (3) JP7492772B2 (https=)
KR (1) KR102671524B1 (https=)
AU (1) AU2020417185B2 (https=)
BR (1) BR112022012998A2 (https=)
WO (1) WO2021138025A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210196748A1 (en) * 2019-12-30 2021-07-01 Robert Olson Composition and therapy for treatment of gag reflexes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB954241A (en) * 1961-05-11 1964-04-02 Koopmans Meelfabrieken N V Process for the production of ready-for-use soups and sauces in powdered form
GB1356097A (en) * 1972-02-25 1974-06-12 Hoffmann La Roche Mineral salt preparation
CN106420810A (zh) * 2016-09-27 2017-02-22 天津市聚星康华医药科技有限公司 一种补液盐口腔溶解膜及其制备方法
CN108354068A (zh) * 2018-05-24 2018-08-03 张继成 一种多功能畜禽补水溶液及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4068006A (en) * 1976-10-07 1978-01-10 Akzona Incorporated Salt seasoning mixture
US4414198A (en) * 1982-04-23 1983-11-08 Joseph Michaelson Rapidly disintegrable tablet composition and method
US4634591A (en) * 1985-09-06 1987-01-06 Westerman Robert D Anti-gagging compositions and method of treating gagging reflexes
DE10015662A1 (de) * 2000-03-29 2001-10-04 Henkel Kgaa Zahnpflegemittel in Portionskapseln
US7799342B2 (en) * 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
US20050019277A1 (en) * 2002-09-11 2005-01-27 The Procter & Gamble Company Tooth whitening products
US7989016B2 (en) * 2006-10-05 2011-08-02 Sambasiva Rao Chigurupati Method for producing a low sodium salt composition
RU2345773C2 (ru) * 2007-01-30 2009-02-10 ФГУ Новосибирский научно-исследовательский институт травматологии и ортопедии (ФГУ ННИИТО Росздрава) Способ ингаляционной анестезии с минимальным газотоком
US20120088971A1 (en) * 2008-03-19 2012-04-12 Hanu Surgical Devices Llc ROTICAM: An Orotracheal Guide with Camera
CA2893780A1 (en) * 2008-04-15 2009-10-22 Trudell Medical International Swallowing air pulse therapy mouthpiece and method for the use thereof
US10556011B2 (en) * 2011-12-02 2020-02-11 Joshua D. Levine Method and system for adding sensory conditioning cues in a pharmacotherapeutic regimen
PL3473248T3 (pl) * 2012-09-11 2022-07-25 Norgine Bv Kompozycje zawierające glikol polietylenowy i siarczany metali alkalicznych lub metali ziem alkalicznych do zastosowania jako kompozycje do oczyszczania jelita grubego
US20140335153A1 (en) * 2013-05-09 2014-11-13 Cure Pharmaceutical Corporation Thin film with high load of active ingredient
EP3131433A1 (en) * 2014-05-07 2017-02-22 Colgate-Palmolive Company Oral care system
US20160271120A1 (en) * 2015-03-17 2016-09-22 Oakdene Holdings Llc Pharmaceutical composition for cleansing of the gastrointestinal tract
US10857092B2 (en) 2019-03-14 2020-12-08 Glen D Lindbo Avoiding gag reflex to enable swallowing pills
KR102245629B1 (ko) * 2019-04-10 2021-04-30 주식회사 제네웰 히알루론산계 녹는 필름, 이의 제조방법 및 이에 사용되는 이형지
US20210196748A1 (en) * 2019-12-30 2021-07-01 Robert Olson Composition and therapy for treatment of gag reflexes
CN112042908A (zh) * 2020-09-14 2020-12-08 湖南雨泉农业发展有限公司 一种无糖保健型葛粉果冻及其制作方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB954241A (en) * 1961-05-11 1964-04-02 Koopmans Meelfabrieken N V Process for the production of ready-for-use soups and sauces in powdered form
GB1356097A (en) * 1972-02-25 1974-06-12 Hoffmann La Roche Mineral salt preparation
CN106420810A (zh) * 2016-09-27 2017-02-22 天津市聚星康华医药科技有限公司 一种补液盐口腔溶解膜及其制备方法
CN108354068A (zh) * 2018-05-24 2018-08-03 张继成 一种多功能畜禽补水溶液及其制备方法

Also Published As

Publication number Publication date
WO2021138025A1 (en) 2021-07-08
JP2024105427A (ja) 2024-08-06
JP7492772B2 (ja) 2024-05-30
US20230025472A1 (en) 2023-01-26
JP2023516851A (ja) 2023-04-21
KR102671524B1 (ko) 2024-05-31
US11813286B2 (en) 2023-11-14
EP4084869A1 (en) 2022-11-09
BR112022012998A2 (pt) 2022-09-06
US11701383B2 (en) 2023-07-18
AU2020417185A1 (en) 2022-07-21
US20210260105A1 (en) 2021-08-26
US20230024303A1 (en) 2023-01-26
US20230414652A1 (en) 2023-12-28
KR20220122680A (ko) 2022-09-02
US20210196748A1 (en) 2021-07-01
CA3163259A1 (en) 2021-07-08
EP4084869A4 (en) 2024-02-14
US11458162B2 (en) 2022-10-04
JP2025166003A (ja) 2025-11-05
JP7724579B2 (ja) 2025-08-18

Similar Documents

Publication Publication Date Title
AU777821B2 (en) Therapeutic compositions and methods of use thereof
JP6762931B2 (ja) 経鼻組成物と該経鼻組成物の使用方法の改善
JP2017132791A (ja) 組み合わせ組成物
TW200418474A (en) Method of treating post-operative nausea and vomiting
AU2010282660B2 (en) Methods for iontophoretically treating nausea and migraine
CA2403994C (en) Nasal administration of agents for the treatment of gastroparesis
US11813286B2 (en) Composition and therapy for treatment of gag reflexes
CA3163259C (en) Composition and therapy for treatment of gag reflexes
CN107582536B (zh) 一种枸橼酸铋钾口腔粘贴片及其制备方法
CN105663029A (zh) 用于口腔给药的生物粘附性缓释凝胶制剂及其制备方法
MX2007009968A (es) Metodo para una politerapia medicamentosa y combinaciones de medicamentos apropiadas para la misma.
JP7745086B2 (ja) ＡＲＮｉとカルシウムイオンアンタゴニストとの医薬組成物および応用
JP2001526217A (ja) 血管性頭痛に対する局所麻酔薬の新規な使用
AU2015305430A1 (en) Method for treating hyperhidrosis
CN102697960A (zh) 一种治疗复发性口腔溃疡的药物及其制备方法
US11813237B2 (en) Creatine, its derivatives, compositions and methods of use thereof
KR100806541B1 (ko) 아세클로페낙을 함유하는 제어 방출성 제제
JP2010174028A (ja) 苦味を有する薬物を含有する口中溶解型又は咀嚼型固形内服医薬組成物
JP4896647B2 (ja) 苦味を有する薬物を含有する口中溶解型又は咀嚼型固形内服医薬組成物
JP2013028647A (ja) 苦味を有する薬物を含有する口中溶解型又は咀嚼型固形内服医薬組成物
CN107260682A (zh) 一种离子vc粉雾剂及其制备方法